SCHEMBL975340

SCHEMBL975340

COc1ccc(NC(=O)N2CCc3nc(C(=O)Nc4ccccc4N)sc3C2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.47
TRPV1 Q8NER1 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
HDAC1 Q13547 4/20 0.45
HDAC2 Q92769 2/20 0.45
F2 P00734 1/20 0.45
F9 P00740 1/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45
F7 P08709 1/20 0.45
PRSS3 P35030 1/20 0.45
NAMPT P43490 1/20 0.45
MAPT P10636 1/20 0.44
HDAC3 O15379 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL976379 0.92 F10 (0.46) F10HDAC1HDAC2F2F9
SCHEMBL978444 0.90 HDAC2 (0.47) F10TRPV1L3MBTL1HDAC1HDAC2
SCHEMBL977792 0.90 F10 (0.51) F10L3MBTL1F2F9PRSS1
SCHEMBL975007 0.89 F10 (0.58) F10HDAC1HDAC2F2F9
SCHEMBL976612 0.89 SIRT5 (0.46) F10TRPV1L3MBTL1HDAC1HDAC2
SCHEMBL976159 0.88 F10 (0.62) F10HDAC1F2F9PRSS1
SCHEMBL976214 0.88 F10 (0.45) F10TRPV1L3MBTL1HDAC1HDAC2
SCHEMBL976131 0.88 F10 (0.43) F10HDAC1HDAC2F2F9
SCHEMBL976130 0.88 F10 (0.43) F10HDAC1HDAC2F2F9
SCHEMBL975192 0.87 HDAC1 (0.54) HDAC1HDAC2HDAC3HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 US claimed
EP-2197552-B1 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2012-11-21 EP claimed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 US claimed
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 US disclosed
EP-2197552-B1 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2012-11-21 EP disclosed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 US disclosed
EP-2197552-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2010-06-23 EP disclosed
WO-2009037001-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC3 F10 2726/4885TRPV1 4524/4885L3MBTL1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.